RADİKAL PROSTATEKTOMİ SPESMENLERİNDEKİ VEGF’İN, E-CADHERİN’İN VE BIM’İN İMMÜNOHİSTOKİMYASAL EKSPRESYONLARININ PROGNOSTİK DEĞERİ

Yıl 2009, Cilt: 22 Sayı: 3, 203 - 216, 19.06.2015

Erem Başok Asıf Yıldırım Adnan Başaran Ebru Zemheri Reşit Tokuç

Öz

Giriş: Bu çalışmanın amacı radikal prostatektomi spesmenlerindeki vasküler büyüme faktörü (VEGF), E-Cadherin ve Bim ekspresyonlarını değerlendirmek ve prognoz üzerine etkisini araştırmaktır.

Gereç ve Yöntem: Radikal prostatektomi uygulanan 66 hastanın (51 hasta pT2, 13 hasta pT3, 2 hasta pT4) spesmenleri VEGF, E-Cadherin ve Bim antikorları ile boyandı. VEGF, E-Cadherin ve Bim immünoreaktivite sonuçlarının Gleason skoru ve biyokimyasal nüks ile olan ilişkileri araştırıldı. İmmünohistokimyasal ve klinik verilere göre istatistiksel analiz yapıldı.

Bulgular: Hastalar Gleason skoruna (Gleson score <7 and Gleason ≥7) ve biyokimyasal nükse (PSA >0,2 ng/ml) göre gruplara ayrıldı. Gruplar arasında VEGF, E-Cadherin ve Bim ekspresyonlarında anlamlı fark olmamasına rağmen, biyokimyasal nüks saptanan hastalarda VEGF ekspresyonu %59,74 ve biyokimyasal nüks saptanmayan hastalarda %44,47 bulundu (p=0,058). Spearman korelasyon testi uygulandığında, VEGF ve E-Cadherin arasında anlamlı bir ilişki tespit edildi (p=0,05).

Sonuç: Tedaviye karar aşamasında yüksek riskli hasta grubunun belirlenmesinde kullanılabilecek biyobelirteçe henüz sahip değiliz. Düşüncemiz daha büyük sayılı çalışmalarda bu biyobelirteçlerin araştırılması ve immünohistokimyasal değerlendirmede imaj analiz yönteminin kullanılmasıdır.

Anahtar Kelimeler: Prostat kanseri, VEGF, E-Cadherin, Bim

Anahtar Kelimeler

Prostat kanseri, VEGF, E-Cadherin, Bim

Kaynakça

• 1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
• 2. Terakawa T, Miyake H, Kanomata N, et al. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. Urology 2008; 72: 1194-1197.
• 3. Acar C, Sözen S, Erdem Ö, ve ark. Prostat kanserinde mikrodamar yoğunluğu, Kİ-67 ve p53 ekspresyonu ile klinikopatolojik ölçütler ve hasta prognozu arasındaki ilişki. Türk Üroloji Dergisi 2006; 32: 478-485.
• 4. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451.
• 5. Him HH, Cho SY, Park DS, et al. Prognostic factors of biochemical recurrence after radical prostatectomy in Korean men with high-risk prostate cancer. EJSO, article in press.
• 6. Eskiçorapçı SY. Prostat kanseri doğal seyri, prognostik faktörler ve nomogramlar. In:Özen H, Türkeri L, eds. Üroonkoloji Kitabı. Üroonkoloji Derneği; Ankara, Ertem Basım Yayın, 2007. 593-603.
• 7. Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growt Factor Rev 1996; 7: 259-270.
• 8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
• 9. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
• 10. Shibue T, Taniguchi T. BH3-only proteins: integrated control points of apoptosis. Int J Cancer 2006; 119: 2036-2043.
• 11. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005; 26: 1317-1322.
• 12. Chipuk JE, Bouchier-Hayes L, Kuwana T, et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735.
• 13. Mungan MU, Gurel D, Canda AE, ve ark. Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma. Eur Urol 2006; 50: 92-97.
• 14. Noldus J, Graefen M, Haese A, et al. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38: 74-78.
• 15. Nicholson B, Theoderescu D. Angiogenesis and prostate cancer tumor growth, J Cell Biochem 2004; 91: 125- 150.
• 16. Claffey KP, Brown LF, Del Aguila LF, et al. Expression of vascular endothelial growth factor by melanoma cells increases tumor growth angiogenesis and experimental metastasis. Cancer Res 1996; 56: 172-177.
• 17. Wu TT, Wang JS, Jiann BP, et al. Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues. J Chin Med Assoc 2007; 70: 380-384.
• 18. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves downregulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57: 1054-1057.
• 19. West AF, O'Donnell M, Charlton RG, et al. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinicopathologic parameters in human prostate cancer. Br J Cancer 2001; 85: 576-583.
• 20. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-1425.
• 21. Oh SJ, Jeltsch MM, Birkenhäger R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997; 188: 96-109.
• 22. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999; 80: 309-313.
• 23. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10: 5137-5144.
• 24. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 2329- 2333.
• 25. Otto T, Birchmeier W, Schmidt U, et al. Inverse relation of E-Cadherin and autocrine motility factor receptor expression as a prognostic factor in patient with bladder carcinomas. Cancer Res 1994; 54: 3120-3123.
• 26. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 6811: 1215-1222.
• 27. Buhmeida A, Pyrhönen S, Laato M, Collan Y. Prognostic factors in prostate cancer. Diagn Pathol 2006; 1: 1-15.
• 28. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased Ecadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-3933.
• 29. van Oort IM, Tomita K, van Bokhoven A, et al. The prognostic value of E-cadherin and the cadherinassociated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 2007; 67: 1432-1438.
• 30. Musiał J, Sporny S, Nowicki A. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol 2007; 58: 235-243.
• 31. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. Ecadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999; 53: 707-713.
• 32. Junior JP, Srougi M, Borra PM, et al. E-cadherin and beta-catenin Loss of Expression Related to Bone Metastasis in Prostate Cancer. Appl Immunohistochem Mol Morphol 2008 Aug 5. [Epub ahead of print]
• 33. Liu JW, Chandra D, Tang SH, et al. Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim. Cancer Res 2002; 62: 2976-2981.
• 34. Howard EW, Leung SC, Yuen HF, et al. Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clin Exp Metastasis 2008; 25: 497-508.
• 35. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208- 213.
• 36. Sinha BK, Yamazaki H, Eliot HM, et al. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim Biophys Acta 1995; 1270: 12-18.
• 37. Concato J, Jain D, Li WW, et al. Molecular markers and mortality in prostate cancer. BJU Int 2007; 100: 1259- 1263.
• 38. Çal Ç, Şimşir A. Prostat kanseri hücrelerinde androjen baskılama tedavisinde direnç gelişiminin mekanizmaları. Türk Üroloji Dergisi 2005; 31: 21-30.
• 39. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992; 52: 6940-6944.
• 40. Colombel M, Olsson CA, Ng PY, Buttyan R. Hormoneregulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992; 52: 4313–4319.
• 41. Teraishi F, Wu S, Inoue S, et al. Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound. Prostate 2006; 66: 430-438.
• 42. Kuniyasu H, Troncoso P, Johnston D, et al. Relative expession of Type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organconfined from pathologically advanced prostate cancer. Clin Cancer Res 2000; 6: 2295-2308.